Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03982069 · ClinicalTrials.gov registry record · Phase 4
Immunologic Response to FluMist vs. Flucelvax
A Phase 4 study of Influenza, Human and Immune Response, sponsored by Richard Zimmerman MD.
- Completed
- Registry status
- Phase 4
- Development phase
- 465
- Enrollment target
- 2
- Study locations
NCT03982069 is a Phase 4 study of Influenza, Human and Immune Response that has completed, run by Richard Zimmerman MD. The registered enrollment target is 465 participants, below the 16,198-participant average among 18 other Influenza, Human trials with a reported enrollment target (97% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT03982069, a Phase 4 study of Influenza, Human and Immune Response, has completed, sponsored by Richard Zimmerman MD.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 465 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to evaluate immunologic response to different types of influenza vaccine among children/adolescents/young adults 4-21 years of age. This is a randomized controlled trial (RCT), that will assess immune response in about 440 participants (about 220 per vaccine arm) pre- and post-vaccination to FluMist (live attenuated influenza vaccine given by nasal administration) and Flucelvax (egg-free cell-culture inactivated influenza vaccine).
Conditions Studied
Interventions
- BIOLOGICAL FluMist live attenuated influenza vaccine
- BIOLOGICAL Flucelvax inactivated influenza vaccine
Study Locations (2)
Pennsylvania
- General Academic Pediatrics - Pittsburgh
- University of Pittsburgh Department of Family Medicine - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 465 participants |
| Start Date | 2019-09-20 |
| Est. Completion | 2020-12-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03982069
The ClinicalTrials.gov registry entry for NCT03982069 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 465 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 16,198-participant average among 18 other Influenza, Human trials with a reported enrollment target (97% lower). The listed sponsor is Richard Zimmerman MD, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Influenza, Human appearing as the primary indexed condition, and to 2 interventions - of which FluMist live attenuated influenza vaccine is the first listed.
NCT03982069 reports 2 study locations spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03982069 about?
NCT03982069 is a clinical study titled "Immunologic Response to FluMist vs. Flucelvax". The purpose of this study is to evaluate immunologic response to different types of influenza vaccine among children/adolescents/young adults 4-21 years of age. This is a randomized controlled trial (RCT), that will assess immune response in about 440 participants (about 220 per vaccine arm) pre- an...
What is the current status of trial NCT03982069?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 465 participants. The study started on 2019-09-20. Estimated completion is 2020-12-09.
What conditions does trial NCT03982069 study?
This clinical trial studies the following conditions: Influenza, Human, Immune Response.
What interventions are being tested in trial NCT03982069?
The interventions under investigation include: FluMist live attenuated influenza vaccine (BIOLOGICAL), Flucelvax inactivated influenza vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT03982069?
This trial is sponsored by Richard Zimmerman MD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03982069 being conducted?
This trial has 2 study locations across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Influenza, Human
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Characterization of Humoral and Cellular Immune Responses Elicited by Influenza Vaccination in Healthy Adults
RECRUITING · Phase 4
-
A Study to Evaluate the Safety and Tolerability of Trivalent Influenza Virus Vaccine in Children Aged 5 Years to < 9 Years
COMPLETED · Phase 4
-
A Study to Evaluate the Immune Response and Safety of an Influenza Vaccine in Adults 18 Years of Age and Above
RECRUITING · Phase 2
-
Flu Infection at UPHS
RECRUITING
-
A Study to Assess the Immune Response and Safety of a Vaccine Against Influenza in Adults 18 Years of Age and Older
ACTIVE NOT RECRUITING · Phase 2
-
A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age
ACTIVE NOT RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.